<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138216</url>
  </required_header>
  <id_info>
    <org_study_id>ADVL0414</org_study_id>
    <secondary_id>COG-ADVL0414</secondary_id>
    <secondary_id>CDR0000440069</secondary_id>
    <nct_id>NCT00138216</nct_id>
  </id_info>
  <brief_title>Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan,
      work in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
      more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when
      given together with temozolomide and vincristine in treating young patients with refractory
      solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose and recommended phase II dose of irinotecan when
           administered with temozolomide and vincristine in young patients with refractory solid
           tumors, including brain tumors.

        -  Determine the toxic effects of this regimen in these patients.

        -  Compare the toxic effects of this regimen in patients with low- vs high-risk UGT1A1
           genotypes.

        -  Determine the pharmacokinetics of irinotecan in these patients.

      Secondary

        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.

        -  Correlate UGT1A1, UGT1A7, UGT1A9, and BCRP genotypes with the pharmacokinetics and
           pharmacodynamics of irinotecan and its metabolites in these patients.

      OUTLINE: This is a multicenter, dose-escalation study of irinotecan. Patients are stratified
      according to UGT1A1 genotype (high-risk [7/7 or 6/7 genotype AND bilirubin ≥ 0.6 mg/dL] vs
      low-risk [absence of high-risk criteria]) if a high-risk patient experiences a dose-limiting
      toxicity (DLT).

      Patients receive oral temozolomide on days 1-5 and oral irinotecan on days 1-5 and 8-12.
      Patients also receive vincristine IV over 1 minute on days 1 and 8. Treatment repeats every
      21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6
      patients experience DLT.

      After completion of study treatment, patients are followed for 1 month and then annually
      thereafter.

      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD) of oral irinotecan</measure>
    <time_frame>length of study</time_frame>
    <description>To estimate the maximum tolerated dose (MTD) of oral irinotecan administered on two different schedules together with fixed-dose temozolomide and vincristine in children with refractory solid tumors or brain tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To preliminarily define the antitumor activity</measure>
    <time_frame>Length of study</time_frame>
    <description>To preliminarily define the antitumor activity of this drug combination within the confines of a Phase 1 study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>see detailed description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Oral Irinotecan, temozolomide and vincristine sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed* malignant solid tumor, including brain tumor, at original
             diagnosis or relapse

               -  Refractory disease NOTE: *Histologic confirmation not required for intrinsic
                  brain stem tumors

          -  Measurable or evaluable disease

          -  No known curative therapy OR therapy proven to prolong survival with an acceptable
             quality of life exists

          -  No known bone marrow metastases

        PATIENT CHARACTERISTICS:

        Age

          -  1 to 21

        Performance status

          -  Lansky 50-100% (for patients ≤ 10 years of age)

          -  Karnofsky 50-100% (for patients &gt; 10 years of age)

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 100,000/mm^3 (transfusion independent)

          -  Hemoglobin ≥ 8.0 g/dL (RBC transfusions allowed)

        Hepatic

          -  ALT ≤ 110 U/L (upper limit of normal [ULN] for ALT is 45 U/L)

          -  Bilirubin ≤ 1.5 times ULN

          -  Albumin ≥ 2 g/dL

        Renal

          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR

          -  Creatinine based on age as follows:

               -  No greater than 0.8 mg/dL (for patients ≤ 5 years of age)

               -  No greater than 1.0 mg/dL (for patients 6 to 10 years of age)

               -  No greater than 1.2 mg/dL (for patients 11 to 15 years of age)

               -  No greater than 1.5 mg/dL (for patients &gt; 15 years of age)

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Neurologic deficits in patients with CNS tumors must be stable for ≥ 1 week prior to
             study entry

          -  No uncontrolled infection

          -  No documented allergy to cephalosporins or dacarbazine

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Recovered from prior immunotherapy

          -  At least 3 months since prior stem cell transplantation or rescue without total-body
             irradiation

               -  No evidence of active graft-versus-host disease

          -  At least 7 days since prior antineoplastic biologic agents

          -  At least 7 days since prior hematopoietic growth factors

          -  No concurrent biologic therapy or immunotherapy

          -  No concurrent prophylactic filgrastim (G-CSF) during the first course of study
             treatment

        Chemotherapy

          -  Recovered from prior chemotherapy

          -  Prior temozolomide, vincristine, irinotecan, or topotecan allowed

               -  No prior coadministration of temozolomide and irinotecan

               -  No disease progression during treatment with either irinotecan or temozolomide

          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for ≥
             7 days prior to study entry

        Radiotherapy

          -  Recovered from prior radiotherapy

          -  At least 6 months since prior total-body irradiation, craniospinal radiotherapy, or
             radiotherapy to ≥ 50% of the pelvis

          -  At least 6 weeks since other prior substantial bone marrow radiotherapy

          -  At least 2 weeks since prior local palliative radiotherapy (small port)

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  No other concurrent investigational drugs

          -  No other concurrent anticancer therapy

          -  No concurrent enzyme-inducing anticonvulsants, including any of the following:

               -  Phenobarbital

               -  Phenytoin

               -  Carbamazepine

               -  Oxcarbazepine

          -  No concurrent administration of any of the following:

               -  Rifampin

               -  Voriconazole

               -  Itraconazole

               -  Ketoconazole

               -  Aprepitant

               -  Hypericum perforatum (St. John's wort)

          -  No concurrent treatment for clostridium difficile infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars M. Wagner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John P. Perentesis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-9786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45. doi: 10.1002/pbc.22407.</citation>
    <PMID>20049936</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

